Second Malignancies after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 10, 2007, Pages 1121-1134

  Lowe, Thomas ^a   Bhatia, Smita ^a   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Allogeneic; PTLD; Second malignancy; Transplant

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CYCLOSPORIN; GANCICLOVIR; GYRASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 ANTIBODY; RITUXIMAB; THALIDOMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; EPSTEIN BARR VIRUS; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS STRAIN;

EPSTEIN-BARR VIRUS INFECTIONS; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS, SECOND PRIMARY; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548661056     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.07.002     Document Type: Review

References (119)

1. Cancer survivors: living longer, and now, better. [editorial]. Lancet 364 (2004) 2153-2154
2. Rowland J., Mariotto A., Aziz N., Tesauro G., and Feuer E.J. Cancer survivorship-United States, 1971-2001. MMWR Morb Mortal Wkly Rep 53 (2004) 526-529
3. Atlas L.D. The National Marrow Donor Program in 2006: constants and challenges. Transfusion 46 (2006) 1080-1084
4. Ries LAG, Harkins D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute (http://seer.cancer.gov/csr/1975_2003/), based on November 2005 SEER data submission, posted to the SEER Web site, 2006.
5. Neugut A.I., Meadows A.T., and Robinson E. Introduction. In: Neugut A.I., Meadows A.T., and Robinson E. (Eds). Multiple Primary Cancers (1999), Lippincott Williams and Wilkins, Philadelphia, PA 1-12
6. Preston D.L., Shimizu Y., Pierce D.A., Suyama A., and Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 160 (2003) 381-407
7. Inskip P.D. Second cancers following radiotherapy. In: Neugut A.I., Meadows A.T., and Robinson E. (Eds). Multiple Primary Cancers (1999), Lippincott Williams and Wilkins, Philadelphia, PA 91-135
8. Tucker M.A., D'Angio G.J., Boice Jr. J.D., et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317 (1987) 588-593
9. UNSCEAR. Sources and Effects of Ionizing Radiation: United Nations Scientific Committee on the Effects of Atomic Radiation 2000 Report to the General Assembly, with Scientific Annexes, Vol II: Effects (2000), United Nations, New York
10. Vega-Stromberg T. Chemotherapy-induced secondary malignancies. J Infus Nurs 26 (2003) 353-361
11. Travis L.B., Curtis R.E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87 (1995) 524-530
12. Pedersen-Bjergaard J., Ersboll J., Hansen V.L., et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide or non-Hodgkin's lymphoma. N Engl J Med 318 (1988) 1028-1032
13. Bhatia S., Robison L.L., Oberlin O., et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334 (1996) 745-751
14. Boivin J.F., Hutchison G.B., and Zauber A.G. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87 (1995) 732-741
15. Garwicz S., Anderson H., Olsen J.H., et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer 88 (2000) 672-678
16. Hawkins M.M., Draper G.J., and Kingston J.E. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 56 (1987) 339-347
17. Neglia J.P., Friedman D.L., Yasui Y., et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 93 (2001) 618-629
18. Van Leeuwen F.E., Klokman W.J., Stovall M., et al. The role of radiation dose, chemotherapy, treatment-related ovarian ablation, and other risk factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2003) 971-980
19. Van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
20. Aisenberg A.C., Finkestein D.M., Doppke K.P., Koerner F.C., Boivin F., and Willett C.G. High risk of breast cancer after irradiation of young women with Hodgkin's disease. Cancer 79 (1997) 1203-1210
21. Hancock S.L., Tucker M.A., and Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer 85 (1993) 25-31
22. Gallagher G., and Forrest D.L. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 109 (2007) 84-92
23. Leisenring W., Friedman D.L., Flowers M.E., Schwartz J.L., and Deeg H.J. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24 (2006) 1119-1126
24. Hasegawa W., Pond G.R., Rifkind J.T., et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 35 (2005) 51-55
25. Baker K.S., DeFor T.E., Burns L.J., Ramsay N.K., Neglia J.P., and Robison L.L. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 21 (2003) 1352-1358
26. Bhatia S., Louie A.D., Bhatia R., et al. Solid cancers after bone marrow transplantation. J Clin Oncol 19 (2001) 464-471
27. Socie G., Curtis R.E., and Deeg H.J. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18 (2000) 348-357
28. Kolb H.J., Socie G., Duell T., et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 131 (1999) 738-744
29. Curtis R.E., Travis L.B., Rowlings P.A., et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94 (1999) 2208-2216
30. Deeg H.J., and Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 91 (1998) 1833-1844
31. Curtis R.E., Rowlings P.A., Deeg H.J., et al. Solid cancers after bone marrow transplantation. N Engl J Med 336 (1997) 897-904
32. Bhatia S., Ramsay L.L., Steinbuch M., et al. Malignant neoplasms, following bone marrow transplantation. Blood 87 (1996) 3633-3639
33. Deeg H.J., Socie G., Schoch G., et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 87 (1996) 386-392
34. Witherspoon R.P., Deeg H.J., and Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation 57 (1994) 1413-1418
35. Pierga J.Y., Socie G., Gluckman E., et al. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiother Oncol 30 (1994) 55-58
36. Lowsky R., Lipton J., Fyles G., et al. Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 12 (1994) 2187-2192
37. Deeg H.J., and Witherspoon R.P. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 7 (1993) 417-429
38. Witherspoon R.P., Storb R., Pepe M., et al. Cumulative incidence of second malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. Blood 79 (1992) 289-290
39. Kolb H.J., Guenther W., Duell T., et al. Cancer after bone marrow transplantation. Bone Marrow Transplant 10 (1992) 135-138
40. Socie G., Henry-Amar M., Cosset J.M., Devergie A., Girinsky T., and Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 78 (1991) 277-279
41. Lishner M., Patterson B., Kandel R., et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 65 (1990) 473-476
42. Witherspoon R.P., Fisher L.D., Schoch G., et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321 (1989) 784-789
43. Shapiro R.S., McClain K., Frizzera G., et al. Ebstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71 (1988) 1234-1243
44. Deeg H.J., Sanders J., Martin P., et al. Secondary malignancies after marrow transplantation. Exp Hematol 12 (1984) 660-666
45. Penn I., Hammon W., Brettschneider L., and Starzl T.E. Malignant lymphomas in transplantation patients. Transplant Proc 1 (1969) 106-112
46. McKhann C.F. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 8 (1969) 209-212
47. Cockfield S.M. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3 (2001) 70-78
48. Orazi A., Hromas R.A., Neiman R.S., et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 107 (1997) 419-429
49. Hoover R.N. Lymphoma risks in populations with altered immunity-a search for mechanism. Cancer Res 52 (1992) 5477s
50. Cohen J.I. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 70 (1991) 137-160
51. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338 (1998) 1413-1421
52. Nalesnik M.A., Makowka L., and Starzl T.E. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 25 (1988) 367-472
53. Lebland V., Davi F., Charlotte F., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 16 (1998) 2052-2059
54. Barker J.N., Martin P.L., Coad J.E., et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 7 (2001) 395-399
55. Gong J.Z., Bayerl M.G., Sandhaus L.M., et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 30 (2006) 328-336
56. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 (2006) 2874-2880
57. Snyder M.J., Stenzel T.T., Buckley P.J., et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 28 (2004) 794-800
58. Frizzera G., Hanto D.W., Gajl-Peczalska K.J., et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 41 (1987) 4262-4279
59. Nalesnik M.A., Jaffe R., Starzl T.E., et al. The pathology of posttransplant lymphoproliferative disroders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133 (1988) 173-192
60. Knowles D.M., Cesarman E., Chadburn A., et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood 85 (1995) 552-565
61. Harris N.L., Ferry J.A., and Swerdlow S.H. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14 (1997) 8-14
62. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification of Tumours vol. 3 (2001), IARC Press, Lyon, France 264-269
63. Gross T., Steinbuch M., DeFor T., et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 23 (1999) 251-258
64. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 10 (2004) 59-65
65. Preiksaitis J.K. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 39 (2004) 1016-1023
66. Hanto D.W., Frizzera G., Gajl-Peczalska K.J., and Simmons R.L. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39 (1985) 461-472
67. Cohen J.I. Epstein-Barr virus lymphoproliferative disease associated with acquired immune deficiency. Medicine 70 (1991) 137-160
68. Henle G., and Henle W. The virus as the etiologic agent of infectious mononucleosis. In: Epstein M.A., and Achong B.G. (Eds). The Epstein-Barr Virus (1979), Springer-Verlag, New York 297-320
69. Wallace L.E., Rickinson A.B., Rowe M., and Epstein M.A. Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 297 (1982) 413-415
70. Pearson G.R., and Orr T.W. Antibody-dependent lymphocyte cytotoxicity against cells experiencing Epstein-Barr virus antigens. J Natl Cancer Inst 56 (1986) 485-488
71. Blazar B.A., Patarroyo M., Klein E., and Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med 151 (1980) 614-627
72. Mathur A., Kamat D.M., Filipovich A.H., et al. Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 57 (1994) 1042-1045
73. Shapiro R.S., McClain K., Frizzera G., et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71 (1988) 1234-1243
74. Andreone P., Gramenzi A., Lorenzini S., et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 163 (2003) 1997-2004
75. Qu L., Xu S., Rowe D., and Triulzi D. Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells. Transfusion 45 (2005) 591-595
76. van Esser J.W., Niesters H.G., van der Holt B., et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99 (2002) 4364-4369
77. Weinstock D.M., Ambrossi G.G., Brennan C., Kiehn T.E., and Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 37 (2006) 539-546
78. Lin J.C., Smith M.C., and Pagano J.S. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine against replication of Epstein-Barr virus. J Virol 50 (1984) 50-55
79. Keay S., Oldach D., Wiland A., et al. Post-transplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 26 (1998) 596-600
80. Davis C.L., Harrison K.L., McVicar J.P., Forg P.J., Bronner M.P., and Marsh C.L. Antiviral prophylaxis and the Epstein-Barr virus-related post-transplant lymphoproliferative disorders. Clin Transplant 9 (1995) 53-59
81. Darenkov I.A., Macarelli M.A., Basadonna G.P., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64 (1997) 848-852
82. Aris R.M., Maia D.M., Neuringer I.P., et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 154 (1996) 1712-1717
83. Kuo P.C., Dafoe D.C., Alfrey E.J., Sibley R.K., and Scandling J.D. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 59 (1995) 135-138
84. Funch D.P., Walker A.M., Schneider G., Ziyadeh N.J., and Pescovitz M.D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5 (2005) 2894-2900
85. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92 (1998) 1549-1555
86. Comoli P., Labirio M., Basso S., et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 99 (2002) 2592-2598
87. Gustafsson A., Levitsky V., Zou J.Z., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95 (2000) 807-814
88. Mourad W.A., Tulabah A., Al Sayed A., et al. The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management. Arch Pathol Lab Med 130 (2006) 1649-1653
89. Pitman S.D., Huang Q., Zuppan C.W., et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 30 (2006) 470-476
90. Blaes A.H., Peterson B.A., Bartlett N., Dunn D.L., and Morrison V.A. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 104 (2005) 1661-1667
91. Codeluppi M., Cocchi S., Guaraldi G., et al. Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: report of three cases. Transplant Proc 37 (2005) 2634-2635
92. Zhu K., Chen J., and Chen S. Treatment of Epstein-Barr virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Hematology 10 (2005) 365-370
93. Oertel S.H., Verschuuren E., Reinke P., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5 (2005) 2901-2906
94. Jain A.B., Marcos A., Pokharna R., et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 80 (2005) 1692-1698
95. Elstrom R.L., Andreadis C., Aqui N.A., et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6 (2006) 569-576
96. Pakakasama S., Eames G.M., Morriss M.C., et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 78 (2004) 755-757
97. Haque T., Wilkie G.M., Taylor C., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360 (2002) 436-442
98. Durandy A. Anti-B and anticytokine therapy for the treatment of posttransplant lymphoproliferative disorder: past, present, and future. Transpl Infect Dis 3 (2001) 104-107
99. Haddad E., Paczesny S., Leblond V., et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97 (2001) 1590-1597
100. Armitage J.O., Carbone P.P., Connors J.M., Levine A., Bennett J.M., and Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21 (2003) 897-906
101. Darrington D.L., Vose J.M., Anderson J.R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12 (1994) 2527-2534
102. Stone R.M., Neuberg D., Soiffer R., et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12 (1994) 2535-2542
103. Krishnan A., Bhatia S., Slovak M.L., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95 (2000) 1588-1593
104. Micallef I.N.M., Lillington D.M., Apostolidis J., et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18 (2000) 947-955
105. Milligan D.W., Ruiz de Elvira M.C., Kolb H.-J., et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT-EBMT Lymphoma and Late Effects Working Parties. Br J Haematol 106 (1999) 1020-1026
106. Tam C.S., Seymour J.F., Prince H.M., et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91 (2006) 1546-1550
107. Fialkow P.J., Thomas E.D., Bryant J.I., and Neiman P.E. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1 (1971) 251-255
108. Cornelius E.A. Rapid viral induction of murine lymphomas in the graft-versus-host reaction. J Exp Med 136 (1972) 1533-1544
109. Schwartz R.S. Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet 1 (1972) 1266-1269
110. Gleichmann E., Melief C.J., and Gleichmann H. Lymphomagenesis and autoimmunization caused by reactions of T-lymphocytes to incompatible structures of the major histocompatibility complex: a concept of pathogenesis. (review). Rec Results Cancer Res 64 (1978) 292-315
111. Thomas E.D., Bryant J.I., Buckner C.D., et al. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1 (1972) 1310-1313
112. Cornelius E.A. Rapid immunological induction of murine lymphomas: evidence for a viral etiology. Science 177 (1972) 524-525
113. Katz F., Reeves B.R., Alexander S., Kearney L., and Chessells J. Leukaemia arising in donor cells following allogeneic bone marrow transplantation for beta thalassaemia demonstrated by immunological, DNA and molecular cytogenetic analysis. Br J Haematol 85 (1993) 326-331
114. Brown S.A., Bashey A., and Schey S.A. Donor cell leukaemia-an unresolved problem. Eur J Haematol 54 (1995) 198-199
115. Niederwieser D.W., Appelbaum F.R., Gastl G., et al. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 322 (1990) 1794-1796
116. Bodo I., Peters M., Radich J.P., et al. Donor-derived acute promyelocytic leukemia in a liver-transplant recipient. N Engl J Med 341 (1999) 807-813
117. Au W.Y., Pang A., Chan E.C., Chu K.M., Shek T.W., and Kwong Y.L. Epstein-barr virus-related gastric adenocarcinoma: an early secondary cancer post hemopoietic stem cell transplantation. Gastroenterology 129 (2005) 2058-2063
118. Hebner C.M., and Laimins L.A. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16 (2006) 83-97
119. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 2.0, March 2006. (www.survivorshipguidelines.org) [accessed May 19, 2007].